PSYCHEMEDICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.55 USD | +0.39% |
|
-0.78% | -13.85% |
| Mar. 28 | Psychemedics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 87.4 | 50.48 | 28.13 | 38.91 | 27.69 | 17.17 |
| Enterprise Value (EV) 1 | 81.05 | 49.16 | 34.2 | 42.04 | 26.51 | 17.51 |
| P/E ratio | 19.1 x | 32.7 x | -7.27 x | -58.5 x | -25.5 x | -4.09 x |
| Yield | 4.54% | 7.87% | 3.54% | 0.71% | 5.71% | 2.36% |
| Capitalization / Revenue | 2.05 x | 1.34 x | 1.32 x | 1.56 x | 1.1 x | 0.78 x |
| EV / Revenue | 1.9 x | 1.3 x | 1.6 x | 1.69 x | 1.05 x | 0.79 x |
| EV / EBITDA | 8.02 x | 7.91 x | -9.17 x | 16.7 x | -30.8 x | -12.5 x |
| EV / FCF | 11.3 x | 9.54 x | -9.36 x | 9.09 x | 4.85 x | 18.9 x |
| FCF Yield | 8.89% | 10.5% | -10.7% | 11% | 20.6% | 5.29% |
| Price to Book | 4.66 x | 3 x | 2.25 x | 3.2 x | 2.59 x | 2.58 x |
| Nbr of stocks (in thousands) | 5,507 | 5,517 | 5,526 | 5,542 | 5,645 | 5,802 |
| Reference price 2 | 15.87 | 9.150 | 5.090 | 7.020 | 4.905 | 2.960 |
| Announcement Date | 3/4/19 | 2/25/20 | 3/26/21 | 3/30/22 | 3/27/23 | 3/28/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 42.67 | 37.68 | 21.36 | 24.91 | 25.24 | 22.1 |
| EBITDA 1 | 10.11 | 6.215 | -3.73 | 2.51 | -0.86 | -1.402 |
| EBIT 1 | 7.61 | 3.798 | -6.066 | 0.209 | -2.883 | -2.921 |
| Operating Margin | 17.83% | 10.08% | -28.4% | 0.84% | -11.42% | -13.22% |
| Earnings before Tax (EBT) 1 | 7.653 | 3.056 | -6.206 | -0.821 | -1.04 | -3.438 |
| Net income 1 | 4.584 | 1.542 | -3.859 | -0.665 | -1.084 | -4.154 |
| Net margin | 10.74% | 4.09% | -18.07% | -2.67% | -4.29% | -18.8% |
| EPS 2 | 0.8300 | 0.2797 | -0.7000 | -0.1200 | -0.1927 | -0.7237 |
| Free Cash Flow 1 | 7.203 | 5.155 | -3.653 | 4.627 | 5.463 | 0.9268 |
| FCF margin | 16.88% | 13.68% | -17.1% | 18.58% | 21.64% | 4.19% |
| FCF Conversion (EBITDA) | 71.25% | 82.94% | - | 184.34% | - | - |
| FCF Conversion (Net income) | 157.13% | 334.3% | - | - | - | - |
| Dividend per Share 2 | 0.7200 | 0.7200 | 0.1800 | 0.0500 | 0.2800 | 0.0700 |
| Announcement Date | 3/4/19 | 2/25/20 | 3/26/21 | 3/30/22 | 3/27/23 | 3/28/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 6.07 | 3.14 | - | 0.33 |
| Net Cash position 1 | 6.35 | 1.32 | - | - | 1.18 | - |
| Leverage (Debt/EBITDA) | - | - | -1.627 x | 1.249 x | - | -0.2382 x |
| Free Cash Flow 1 | 7.2 | 5.15 | -3.65 | 4.63 | 5.46 | 0.93 |
| ROE (net income / shareholders' equity) | 24.5% | 8.67% | -26.3% | -5.37% | -9.42% | -47.6% |
| ROA (Net income/ Total Assets) | 18.5% | 9.04% | -14.7% | 0.57% | -8.95% | -11.8% |
| Assets 1 | 24.81 | 17.05 | 26.23 | -116 | 12.12 | 35.33 |
| Book Value Per Share 2 | 3.400 | 3.050 | 2.260 | 2.190 | 1.900 | 1.150 |
| Cash Flow per Share 2 | 0.7400 | 1.320 | 0.5100 | 0.3600 | 0.8400 | 0.3400 |
| Capex 1 | 1.19 | 1.68 | 0.99 | 0.18 | 0.19 | 0.16 |
| Capex / Sales | 2.79% | 4.45% | 4.64% | 0.73% | 0.74% | 0.71% |
| Announcement Date | 3/4/19 | 2/25/20 | 3/26/21 | 3/30/22 | 3/27/23 | 3/28/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.85% | 14.8M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- PMD Stock
- Financials Psychemedics Corporation
